Total
0
Shares
Kalytera Therapeutics receives positive results from drug study
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Rapid Dose Therapeutics (DOSE) signs exclusive manufacturing and distribution agreement with MapleX Naturals Inc
  • The flagship product ‘QuickStrip™’ is a thin, orally dissolvable film delivered quickly into the bloodstream bypassing first-pass metabolism resulting in rapid onset of the active ingredient
  • MapleX products are currently distributed in specialty retail locations across Canada
  • Rapid Dose Therapeutics is a publicly traded Canadian life sciences company providing innovative, proprietary drug delivery technologies
  • Rapid Dose Therapeutics Corp. (DOSE) is up 11.90 per cent and is trading at C$0.24 at 10:48 am ET

Rapid Dose Therapeutics Corp. (DOSE) is a Canadian Life Science company focused on innovative drug and active ingredient delivery solutions.

The flagship product ‘QuickStrip™’ is a thin, orally dissolvable film, infused with an active ingredient delivered quickly into the bloodstream bypassing first-pass metabolism resulting in rapid onset of the active ingredient.

Rapid Dose has entered into an exclusive manufacturing and distribution agreement with MapleX Naturals Inc. (“MapleX”) for its personal care product line of topical creams and lotions.

These ointments are infused with natural ingredients such as hemp and Canadian maple syrup, for sale by Rapid Dose to retailers across North America.

MapleX was a founding shareholder in Consolidated Craft Brands, recently acquired by and amalgamated into a wholly-owned subsidiary of RDT.

MapleX has significant experience “infusing Hemp” extracts (rich in Omega 3,6 and 9) into high-end personal care products to provide a “humectant” that repairs the skin, locks in moisture, regulates oil production, reduces inflammation, and visibly smooths the skin.

MapleX products are currently distributed in specialty retail locations across Canada.

Dave Thompson, CEO of MapleX, commented, “We are excited to enter into this agreement with RDT. As a result, we look forward to providing customers in Canada and later in the United States with our MapleX product line."

Mark Upsdell, CEO of RDT, commented, “The agreement with MapleX is key to our product line expansion as we continue to grow our health and wellness portfolio of products to augment the opportunities from our ‘QuickStrip™ technology."

"We have already shipped our first topical products and look forward to seeing them in retailers across Canada in the coming weeks,” added Upsdell.

Rapid Dose Therapeutics is a publicly-traded Canadian life sciences company providing innovative, proprietary drug delivery technologies designed to improve life outcomes and quality.

Rapid Dose Therapeutics Corp. (DOSE) is up 11.90 per cent and is trading at C$0.24 at 10:48 am ET.

More From The Market Herald
VitalHub - President and CEO, Dan Matlow - The Market Herald Canada

" VitalHub (TSXV:VHI) to commence trading on the TSX

VitalHub (VHI) begins trading on the Toronto Stock Exchange on September 23, 2021.
BetterLife Pharma - CEO, Ahmad Doroudian. - The Market Herald Canada

" BetterLife (CSE:BETR) enrolls first patient in Interferon alpha-2b COVID-19 trial

The first patient has been enrolled in BetterLife’s (BETR) Interferon alpha-2b COVID-19 trial in Chile.
International Consolidated Uranium (TSXV:CUR) partners with Mars Investor Relations

" Algernon Pharmaceuticals (CSE:AGN) welcomes Dr. Mark Williams to the board

Algernon Pharmaceuticals (AGN) is pleased to announce that Dr. Mark Williams has been appointed as a member of the Board of Directors.
Small Pharma - CEO, Peter Rands (third from left) and the Small Pharma team. - The Market Herald Canada

" Negev Capital doubles down on Small Pharma (TSXV:DMT)

Negev Capital, a psychedelic medical intervention fund, has doubled its investment in Small Pharma (DMT).